<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Verici Dx Plc — News on 6ix</title>
    <link>https://6ix.com/company/verici-dx-plc</link>
    <description>Latest news and press releases for Verici Dx Plc on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Thu, 16 Apr 2026 06:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/verici-dx-plc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835ef8b78dffbe2df12c87b.webp</url>
      <title>Verici Dx Plc</title>
      <link>https://6ix.com/company/verici-dx-plc</link>
    </image>
    <item>
      <title>Positive Q1 Trading Update</title>
      <link>https://6ix.com/company/verici-dx-plc/news/positive-q1-trading-update</link>
      <guid isPermaLink="true">https://6ix.com/company/verici-dx-plc/news/positive-q1-trading-update</guid>
      <pubDate>Thu, 16 Apr 2026 06:00:00 GMT</pubDate>
      <description>Verici Dx plc reported a strong first quarter for 2026, with Tutivia™ testing volumes increasing 32% quarter-on-quarter to 392 and 34% year-on-year, exceeding management expectations. Seven new transplant centres ordered tests, and one centre integrated Tutivia™ into its clinical protocols. Repeat ordering centres showed significant growth, with six increasing volumes by over 20%, and two of the largest centres seeing more than 30% growth. Tutivia™ is now approved in 17 US State Medicaid program</description>
    </item>
    <item>
      <title>Board Change</title>
      <link>https://6ix.com/company/verici-dx-plc/news/board-change-186</link>
      <guid isPermaLink="true">https://6ix.com/company/verici-dx-plc/news/board-change-186</guid>
      <pubDate>Tue, 31 Mar 2026 06:00:00 GMT</pubDate>
      <description>Verici Dx Plc announced that Non-Executive Director James McCullough has resigned from the Board with immediate effect to focus on his CEO role at Renalytix plc, and the company has commenced its search for a replacement.
                Disclaimer*</description>
    </item>
    <item>
      <title>FY25 Trading Update</title>
      <link>https://6ix.com/company/verici-dx-plc/news/fy25-trading-update-5</link>
      <guid isPermaLink="true">https://6ix.com/company/verici-dx-plc/news/fy25-trading-update-5</guid>
      <pubDate>Thu, 05 Feb 2026 07:01:00 GMT</pubDate>
      <description>Verici Dx plc reported strong growth in FY25, with unaudited revenues reaching $3.8 million, up from $3.3 million in 2024, driven by $3.0 million in recognised revenue from Tutivia tests, for which $3.2 million worth were ordered. License income contributed $0.8 million, reflecting expected milestone payments. The company ended the year with $3.3 million in cash, slightly exceeding expectations, and $1.6 million in accounts receivable, supporting a cash runway into the second half of 2026. Key o</description>
    </item>
    <item>
      <title>Agreement with BCBS of Illinois for Tutivia™</title>
      <link>https://6ix.com/company/verici-dx-plc/news/agreement-with-bcbs-of-illinois-for-tutiviatm</link>
      <guid isPermaLink="true">https://6ix.com/company/verici-dx-plc/news/agreement-with-bcbs-of-illinois-for-tutiviatm</guid>
      <pubDate>Thu, 05 Feb 2026 07:00:00 GMT</pubDate>
      <description>Verici Dx plc has secured a significant agreement with Blue Cross and Blue Shield of Illinois for its Tutivia™ post-kidney transplant test, which is designed for the early detection of acute rejection. This agreement establishes Tutivia™ as an in-network benefit for patients, simplifying the claims process and ensuring in-network rates, and also grants Verici Dx membership in BCBS&apos;s Preferred Provider Organization network, opening access to other BCBS entities like BCBS Texas. The agreement exte</description>
    </item>
    <item>
      <title>Completion of CAP accreditation audit</title>
      <link>https://6ix.com/company/verici-dx-plc/news/completion-of-cap-accreditation-audit</link>
      <guid isPermaLink="true">https://6ix.com/company/verici-dx-plc/news/completion-of-cap-accreditation-audit</guid>
      <pubDate>Wed, 12 Nov 2025 07:00:00 GMT</pubDate>
      <description>Verici Dx Plc has successfully completed its second biennial inspection by the College of American Pathologists (CAP) for its clinical laboratory, passing with no deficiencies. This accreditation is crucial for maintaining high standards in clinical laboratory practice and ensuring the reliability of test results for organ transplant diagnostics, which directly supports the company&apos;s commitment to patient health and its role as a trusted partner to clinicians.
                Disclaimer*</description>
    </item>
    <item>
      <title>Provider Participation Agreement with Prime Health</title>
      <link>https://6ix.com/company/verici-dx-plc/news/provider-participation-agreement-with-prime-health</link>
      <guid isPermaLink="true">https://6ix.com/company/verici-dx-plc/news/provider-participation-agreement-with-prime-health</guid>
      <pubDate>Thu, 06 Nov 2025 07:00:00 GMT</pubDate>
      <description>Provider Participation Agreement with Prime Health.</description>
    </item>
    <item>
      <title>Completion of ISO 27001 surveillance audit</title>
      <link>https://6ix.com/company/verici-dx-plc/news/completion-of-iso-27001-surveillance-audit</link>
      <guid isPermaLink="true">https://6ix.com/company/verici-dx-plc/news/completion-of-iso-27001-surveillance-audit</guid>
      <pubDate>Mon, 03 Nov 2025 07:00:00 GMT</pubDate>
      <description>Verici Dx PLC announced the successful completion of its annual surveillance audit for ISO 27001:2022 certification. This certification is a globally recognized standard specifying data privacy and security requirements for an Information Security Management System. The successful completion reinforces the company&apos;s position as a trusted partner, demonstrating its commitment to protecting sensitive data and information. Continued conformity with the standard means Verici Dx&apos;s system meets worldw</description>
    </item>
    <item>
      <title>Options revision &amp; Grant of new share options</title>
      <link>https://6ix.com/company/verici-dx-plc/news/options-revision-and-grant-of-new-share-options</link>
      <guid isPermaLink="true">https://6ix.com/company/verici-dx-plc/news/options-revision-and-grant-of-new-share-options</guid>
      <pubDate>Thu, 30 Oct 2025 07:00:00 GMT</pubDate>
      <description>Verici Dx PLC has revised certain existing share options and granted new share options to directors, PDMRs, employees, and consultants. The company repriced options over 15,577,304 ordinary shares, changing the exercise price for Sara Barrington, David Anderson, and Lorenzo Gallon from £0.20 to £0.00525 per share. Additionally, new share options were granted over 107,800,000 ordinary shares at an exercise price of £0.00525 per share, including 54,900,000 to Sara Barrington, 6,800,000 to David An</description>
    </item>
    <item>
      <title>Board Changes</title>
      <link>https://6ix.com/company/verici-dx-plc/news/board-changes-93</link>
      <guid isPermaLink="true">https://6ix.com/company/verici-dx-plc/news/board-changes-93</guid>
      <pubDate>Mon, 06 Oct 2025 06:01:00 GMT</pubDate>
      <description>Verici Dx plc announced the appointment of Aubrey Powell as a Non-executive Director, effective immediately. Concurrently, Dr. Erik Lium, who had served as a Non-executive Director since August 2020, stepped down from the Board, also with immediate effect. Powell brings over 30 years of experience supporting growth companies, with 26 years in investment banking and corporate finance. He previously acted as the lead member of the advisory team at Singer Capital Markets. Powell currently holds a d</description>
    </item>
    <item>
      <title>Update on Tutivia™ test adoption</title>
      <link>https://6ix.com/company/verici-dx-plc/news/update-on-tutiviatm-test-adoption</link>
      <guid isPermaLink="true">https://6ix.com/company/verici-dx-plc/news/update-on-tutiviatm-test-adoption</guid>
      <pubDate>Mon, 06 Oct 2025 06:00:00 GMT</pubDate>
      <description>Verici Dx PLC reported progress in Tutivia test adoption following their July equity fundraise. In Q3, the company saw a 19% increase in ordering clinicians and added nine new transplant centers, bringing the total to 30 onboarded centers. These centers represent 16% of annual transplants in the US. The company also expanded its commercial team with three new senior sales hires and will add a Director of Clinical Partnerships in mid-October. The number of orders in Q3 were consistent with the pr</description>
    </item>
    <item>
      <title>Holding(s) in Company</title>
      <link>https://6ix.com/company/verici-dx-plc/news/holdings-in-company-353</link>
      <guid isPermaLink="true">https://6ix.com/company/verici-dx-plc/news/holdings-in-company-353</guid>
      <pubDate>Wed, 01 Oct 2025 15:55:00 GMT</pubDate>
      <description>On September 30, 2025, Harwood Capital LLP&apos;s voting rights in Verici Dx PLC fell below a notifiable threshold. The resulting situation shows Harwood Capital LLP now holds 12.756% of the voting rights attached to shares, a decrease from the previously notified 13.074%. This comprises 193,065,843 voting rights. Specifically, Oryx International Growth Fund Limited holds 3.832% of voting rights, North Atlantic Smaller Companies Investment Trust Plc holds 8.127%, and Harwood Capital LLP directly hold</description>
    </item>
    <item>
      <title>Half-year Report</title>
      <link>https://6ix.com/company/verici-dx-plc/news/half-year-report-174</link>
      <guid isPermaLink="true">https://6ix.com/company/verici-dx-plc/news/half-year-report-174</guid>
      <pubDate>Tue, 30 Sep 2025 06:00:00 GMT</pubDate>
      <description>Verici Dx plc reported its unaudited interim results for the six months ended June 30, 2025, showing revenue of $1.9 million, including $1.16 million from Tutivia™ testing revenues and $0.75 million from Thermo Fisher licensing revenues. The EBITDA loss was $2.8 million, and the net cash outflow from operating activities was $3.5 million. The company&apos;s cash balance as of June 30, 2025, was $0.5 million, increasing to approximately $5.3 million by September 30, 2025. Post period end, Verici Dx ra</description>
    </item>
    <item>
      <title>Tutivia™ abstracts for World Transplant Congress</title>
      <link>https://6ix.com/company/verici-dx-plc/news/tutiviatm-abstracts-for-world-transplant-congress</link>
      <guid isPermaLink="true">https://6ix.com/company/verici-dx-plc/news/tutiviatm-abstracts-for-world-transplant-congress</guid>
      <pubDate>Thu, 31 Jul 2025 06:00:00 GMT</pubDate>
      <description>Tutivia™ abstracts for World Transplant Congress.</description>
    </item>
    <item>
      <title>Result of Annual General Meeting</title>
      <link>https://6ix.com/company/verici-dx-plc/news/result-of-annual-general-meeting-61</link>
      <guid isPermaLink="true">https://6ix.com/company/verici-dx-plc/news/result-of-annual-general-meeting-61</guid>
      <pubDate>Wed, 30 Jul 2025 06:00:00 GMT</pubDate>
      <description>Result of Annual General Meeting.</description>
    </item>
    <item>
      <title>Result of WRAP Retail Offer</title>
      <link>https://6ix.com/company/verici-dx-plc/news/result-of-wrap-retail-offer-3</link>
      <guid isPermaLink="true">https://6ix.com/company/verici-dx-plc/news/result-of-wrap-retail-offer-3</guid>
      <pubDate>Tue, 29 Jul 2025 06:00:00 GMT</pubDate>
      <description>Result of WRAP Retail Offer.</description>
    </item>
    <item>
      <title>WRAP Retail Offer for up to £500,000</title>
      <link>https://6ix.com/company/verici-dx-plc/news/wrap-retail-offer-for-up-to-pound500000</link>
      <guid isPermaLink="true">https://6ix.com/company/verici-dx-plc/news/wrap-retail-offer-for-up-to-pound500000</guid>
      <pubDate>Tue, 22 Jul 2025 06:00:00 GMT</pubDate>
      <description>WRAP Retail Offer for up to £500,000.</description>
    </item>
    <item>
      <title>Result of Placing &amp; Subscription</title>
      <link>https://6ix.com/company/verici-dx-plc/news/result-of-placing-and-subscription-8</link>
      <guid isPermaLink="true">https://6ix.com/company/verici-dx-plc/news/result-of-placing-and-subscription-8</guid>
      <pubDate>Mon, 21 Jul 2025 14:43:00 GMT</pubDate>
      <description>Result of Placing &amp; Subscription.</description>
    </item>
    <item>
      <title>Proposed Fundraising</title>
      <link>https://6ix.com/company/verici-dx-plc/news/proposed-fundraising-9</link>
      <guid isPermaLink="true">https://6ix.com/company/verici-dx-plc/news/proposed-fundraising-9</guid>
      <pubDate>Mon, 21 Jul 2025 06:00:00 GMT</pubDate>
      <description>Proposed Fundraising.</description>
    </item>
    <item>
      <title>Final Results</title>
      <link>https://6ix.com/company/verici-dx-plc/news/final-results-176</link>
      <guid isPermaLink="true">https://6ix.com/company/verici-dx-plc/news/final-results-176</guid>
      <pubDate>Mon, 30 Jun 2025 06:00:00 GMT</pubDate>
      <description>Final Results.</description>
    </item>
    <item>
      <title>Update on funding to accelerate commercial growth</title>
      <link>https://6ix.com/company/verici-dx-plc/news/update-on-funding-to-accelerate-commercial-growth</link>
      <guid isPermaLink="true">https://6ix.com/company/verici-dx-plc/news/update-on-funding-to-accelerate-commercial-growth</guid>
      <pubDate>Wed, 11 Jun 2025 06:00:00 GMT</pubDate>
      <description>Update on funding to accelerate commercial growth.</description>
    </item>
  </channel>
</rss>